Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

273 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Treatment of posttransplant lymphoproliferative disorder with the anti-CD20 monoclonal antibody rituximab alone in an adult after liver transplantation: a new drug in therapy of patients with posttransplant lymphoproliferative disorder after solid organ transplantation?
Oertel SH, Anagnostopoulos I, Bechstein WO, Liehr H, Riess HB. Oertel SH, et al. Among authors: anagnostopoulos i. Transplantation. 2000 Feb 15;69(3):430-2. doi: 10.1097/00007890-200002150-00021. Transplantation. 2000. PMID: 10706055
Salvage therapy for relapsed posttransplant lymphoproliferative disorders (PTLD) with a second progression of PTLD after Upfront chemotherapy: the role of single-agent rituximab.
Trappe RU, Choquet S, Reinke P, Dreyling M, Mergenthaler HG, Jäger U, Kebelmann-Betzing C, Jonas S, Lehmkuhl H, Anagnostopoulos I, Leblond V, Hetzer R, Dörken B, Riess H, Oertel S. Trappe RU, et al. Among authors: anagnostopoulos i. Transplantation. 2007 Dec 27;84(12):1708-12. doi: 10.1097/01.tp.0000295987.12996.19. Transplantation. 2007. PMID: 18165786
Efficiency of antiviral therapy plus IVIG in a case of primary EBV infection associated PTLD refractory to rituximab, chemotherapy, and antiviral therapy alone.
Trappe R, Riess H, Anagnostopoulos I, Neuhaus R, Gärtner BC, Pohl H, Müller HP, Jonas S, Papp-Vary M, Oertel S. Trappe R, et al. Among authors: anagnostopoulos i. Ann Hematol. 2009 Feb;88(2):167-72. doi: 10.1007/s00277-008-0538-0. Epub 2008 Jul 18. Ann Hematol. 2009. PMID: 18636261 No abstract available.
Treatment of PTLD with rituximab and CHOP reduces the risk of renal graft impairment after reduction of immunosuppression.
Trappe R, Hinrichs C, Appel U, Babel N, Reinke P, Neumayer HH, Budde K, Dreyling M, Dührsen U, Kliem V, Schüttrumpf S, Hauser IA, Mergenthaler HG, Schlattmann P, Anagnostopoulos I, Doerken B, Riess H. Trappe R, et al. Among authors: anagnostopoulos i. Am J Transplant. 2009 Oct;9(10):2331-7. doi: 10.1111/j.1600-6143.2009.02772.x. Epub 2009 Aug 6. Am J Transplant. 2009. PMID: 19663889 Free article.
IL-6 and IL-10 in post-transplant lymphoproliferative disorders development and maintenance: a longitudinal study of cytokine plasma levels and T-cell subsets in 38 patients undergoing treatment.
Hinrichs C, Wendland S, Zimmermann H, Eurich D, Neuhaus R, Schlattmann P, Babel N, Riess H, Gärtner B, Anagnostopoulos I, Reinke P, Trappe RU. Hinrichs C, et al. Among authors: anagnostopoulos i. Transpl Int. 2011 Sep;24(9):892-903. doi: 10.1111/j.1432-2277.2011.01282.x. Epub 2011 Jun 11. Transpl Int. 2011. PMID: 21668529 Free article. Clinical Trial.
273 results